欧林生物拟收购控股子公司15%股权，终止以简易程序向特定对象发行股票事项

Core Viewpoint - The company plans to acquire a total of 15% equity in its subsidiary, XinNuoMing Bio, from minority shareholders through a public transfer at a price not exceeding RMB 45 million, enhancing control and management efficiency [1][2]. Group 1: Acquisition Details - The company intends to purchase 8.11% of XinNuoMing Bio from Fund No. 1 and 6.89% from JingChuang Fund [1]. - The acquisition will increase the company's stake in XinNuoMing Bio from 84.13% to 99.13% post-transaction [1][2]. Group 2: Strategic Implications - The acquisition is expected to improve the company's control over its subsidiary and enhance overall strategic synergy and resource integration [2]. - The transaction will not change the scope of consolidation and will not adversely affect the company's financial status or operating results [2]. Group 3: Business Focus and R&D - The company specializes in the research, production, and sales of human vaccines, with a strong focus on developing vaccines for "super bacteria" and "adult vaccines" [2][3]. - The company is advancing four global Class 1 new drug projects related to the World Health Organization's list of the 12 most dangerous antibiotic-resistant bacteria [3]. Group 4: Financial Activities - The company previously announced plans to issue A-shares to specific investors, aiming to raise RMB 125 million for vaccine R&D and production base upgrades [3]. - However, the company has decided to terminate this share issuance due to market conditions and other factors, ensuring that daily operations remain unaffected [4].